Which has better valuation and earnings, CV or CDRE?

Cadre has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.56M 27.87 -$25.32M -$2.34 N/A Cadre $610.31M 2.12 $44.14M $0.89 34.00

Is CV or CDRE more profitable?

Cadre has a net margin of 5.80% compared to CapsoVision's net margin of -198.87%. Cadre's return on equity of 12.39% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Cadre 5.80% 12.39% 5.08%

Is ENOV or CV more profitable?

Enovis has a net margin of -49.92% compared to CapsoVision's net margin of -198.87%. Enovis' return on equity of 10.32% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% CapsoVision -198.87% N/A -136.03%

CapsoVision (CV) Competitors

$7.56 +0.74 (+10.76%)

Closing price 06/4/2026 03:59 PM Eastern

Extended Trading

$7.64 +0.08 (+1.06%)

As of 04:43 AM Eastern

Compare

CV vs. CDRE, TNDM, BLFS, EYE, and ENOV

Should you buy CapsoVision stock or one of its competitors? MarketBeat compares CapsoVision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CapsoVision include Cadre (CDRE), Tandem Diabetes Care (TNDM), BioLife Solutions (BLFS), National Vision (EYE), and Enovis (ENOV). These companies are all part of the "medical equipment" industry.

How does CapsoVision compare to Cadre?

CapsoVision (NASDAQ:CV) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

44.0% of Cadre shares are held by institutional investors. 2.3% of CapsoVision shares are held by company insiders. Comparatively, 30.1% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CapsoVision pays an annual dividend of $0.92 per share and has a dividend yield of 12.2%. Cadre pays an annual dividend of $0.40 per share and has a dividend yield of 1.3%. CapsoVision pays out -39.3% of its earnings in the form of a dividend. Cadre pays out 44.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cadre has raised its dividend for 2 consecutive years. CapsoVision is clearly the better dividend stock, given its higher yield and lower payout ratio.

Cadre has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.87	-$25.32M	-$2.34	N/A
Cadre	$610.31M	2.12	$44.14M	$0.89	34.00

In the previous week, Cadre had 5 more articles in the media than CapsoVision. MarketBeat recorded 5 mentions for Cadre and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat Cadre's score of 0.29 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
Cadre	Neutral

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 12.36%. Cadre has a consensus target price of $39.75, suggesting a potential upside of 31.34%. Given Cadre's higher probable upside, analysts clearly believe Cadre is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

Cadre has a net margin of 5.80% compared to CapsoVision's net margin of -198.87%. Cadre's return on equity of 12.39% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Cadre	5.80%	12.39%	5.08%

Summary

Cadre beats CapsoVision on 13 of the 18 factors compared between the two stocks.

How does CapsoVision compare to Tandem Diabetes Care?

CapsoVision (NASDAQ:CV) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

CapsoVision currently has a consensus price target of $8.50, suggesting a potential upside of 12.36%. Tandem Diabetes Care has a consensus price target of $29.84, suggesting a potential upside of 53.43%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57

In the previous week, Tandem Diabetes Care had 2 more articles in the media than CapsoVision. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat Tandem Diabetes Care's score of 0.95 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
Tandem Diabetes Care	Positive

CapsoVision has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.87	-$25.32M	-$2.34	N/A
Tandem Diabetes Care	$1.01B	1.31	-$204.71M	-$1.40	N/A

Tandem Diabetes Care has a net margin of -9.20% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Summary

Tandem Diabetes Care beats CapsoVision on 9 of the 14 factors compared between the two stocks.

How does CapsoVision compare to BioLife Solutions?

CapsoVision (NASDAQ:CV) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, BioLife Solutions had 10 more articles in the media than CapsoVision. MarketBeat recorded 10 mentions for BioLife Solutions and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat BioLife Solutions' score of 0.31 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
BioLife Solutions	Neutral

CapsoVision presently has a consensus target price of $8.50, indicating a potential upside of 12.36%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 18.12%. Given BioLife Solutions' higher probable upside, analysts plainly believe BioLife Solutions is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

BioLife Solutions has a net margin of -2.80% compared to CapsoVision's net margin of -198.87%. BioLife Solutions' return on equity of 1.81% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
BioLife Solutions	-2.80%	1.81%	1.65%

93.2% of BioLife Solutions shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioLife Solutions has higher revenue and earnings than CapsoVision. BioLife Solutions is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.87	-$25.32M	-$2.34	N/A
BioLife Solutions	$96.21M	13.76	-$4.59M	-$0.08	N/A

Summary

BioLife Solutions beats CapsoVision on 10 of the 16 factors compared between the two stocks.

How does CapsoVision compare to National Vision?

CapsoVision (NASDAQ:CV) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

National Vision has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	27.87	-$25.32M	-$2.34	N/A
National Vision	$2.02B	0.61	$29.60M	$0.57	27.19

CapsoVision currently has a consensus price target of $8.50, indicating a potential upside of 12.36%. National Vision has a consensus price target of $30.08, indicating a potential upside of 94.09%. Given National Vision's stronger consensus rating and higher probable upside, analysts clearly believe National Vision is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, National Vision had 4 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for National Vision and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat National Vision's score of 1.21 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
National Vision	Positive

National Vision has a net margin of 2.31% compared to CapsoVision's net margin of -198.87%. National Vision's return on equity of 6.41% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
National Vision	2.31%	6.41%	2.81%

Summary

National Vision beats CapsoVision on 11 of the 14 factors compared between the two stocks.

How does CapsoVision compare to Enovis?

Enovis (NYSE:ENOV) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

98.5% of Enovis shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Enovis had 6 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Enovis and 0 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat Enovis' score of 0.55 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Enovis	Positive
CapsoVision	Very Positive

Enovis currently has a consensus target price of $44.50, suggesting a potential upside of 94.71%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 12.36%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Enovis has a net margin of -49.92% compared to CapsoVision's net margin of -198.87%. Enovis' return on equity of 10.32% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
CapsoVision	-198.87%	N/A	-136.03%

CapsoVision has lower revenue, but higher earnings than Enovis. CapsoVision is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.59	-$1.18B	-$19.88	N/A
CapsoVision	$13.56M	27.87	-$25.32M	-$2.34	N/A

Summary

Enovis beats CapsoVision on 11 of the 16 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$341.25M	$2.63B	$4.34B	$12.43B
Dividend Yield	N/A	N/A	7.93%	5.33%
P/E Ratio	-3.23	1.93	21.70	24.34
Price / Sales	27.87	463.16	232.28	115.17
Price / Cash	N/A	7.78	53.68	55.53
Price / Book	27.02	6.52	30.95	6.72
Net Income	-$25.32M	-$69.38M	$109.80M	$337.03M
7 Day Performance	11.58%	-1.36%	-0.49%	-0.13%
1 Month Performance	7.15%	0.53%	4.51%	3.76%
1 Year Performance	N/A	39.97%	15.47%	34.36%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	1.2536 of 5 stars	$7.57 +10.8%	$8.50 +12.4%	N/A	$341.25M	$13.56M	N/A	90	Positive News High Trading Volume
CDRE Cadre	4.5652 of 5 stars	$30.68 -1.5%	$39.75 +29.6%	-11.2%	$1.31B	$610.31M	34.47	2,533
TNDM Tandem Diabetes Care	3.0217 of 5 stars	$19.12 +11.2%	$29.84 +56.1%	-3.6%	$1.31B	$1.01B	N/A	2,500	Gap Up High Trading Volume
BLFS BioLife Solutions	2.3162 of 5 stars	$26.63 +6.9%	$32.00 +20.2%	+23.0%	$1.30B	$96.21M	N/A	440	Analyst Revision High Trading Volume
EYE National Vision	4.7277 of 5 stars	$16.08 -4.0%	$30.08 +87.1%	-25.8%	$1.29B	$1.99B	28.21	13,138

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. CDRE, TNDM, BLFS, EYE, and ENOV

How does CapsoVision compare to Cadre?

Summary

How does CapsoVision compare to Tandem Diabetes Care?

Summary

How does CapsoVision compare to BioLife Solutions?

Summary

How does CapsoVision compare to National Vision?

Summary

How does CapsoVision compare to Enovis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. CDRE, TNDM, BLFS, EYE, and ENOV

How does CapsoVision compare to Cadre?

Do insiders and institutionals hold more shares of CV or CDRE?

Is CV or CDRE a better dividend stock?

Which has better valuation and earnings, CV or CDRE?

Does the media favor CV or CDRE?

Do analysts prefer CV or CDRE?

Is CV or CDRE more profitable?

Summary

How does CapsoVision compare to Tandem Diabetes Care?

Do analysts rate CV or TNDM?

Does the media favor CV or TNDM?

Which has preferable valuation & earnings, CV or TNDM?

Is CV or TNDM more profitable?

Summary

How does CapsoVision compare to BioLife Solutions?

Does the media refer more to CV or BLFS?

Do analysts rate CV or BLFS?

Is CV or BLFS more profitable?

Do institutionals & insiders believe in CV or BLFS?

Which has better valuation and earnings, CV or BLFS?

Summary

How does CapsoVision compare to National Vision?

Which has preferable earnings & valuation, CV or EYE?

Do analysts rate CV or EYE?

Does the media prefer CV or EYE?

Is CV or EYE more profitable?

Summary

How does CapsoVision compare to Enovis?

Do institutionals and insiders have more ownership in ENOV or CV?

Does the media refer more to ENOV or CV?

Do analysts rate ENOV or CV?

Is ENOV or CV more profitable?

Which has better earnings and valuation, ENOV or CV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools